Live tape
Top 8, mentions 7d7,542META2,264 mentions▲ +0.06GOOGL1,512 mentions▲ +0.02NVDA804 mentions▲ +0.09MUSE666 mentions▲ +0.07MSFT606 mentions▲ +0.06SPY572 mentions▲ +0.05QQQ564 mentions▲ +0.08TSLA554 mentions▲ +0.06

Equity · Healthcare

OGN

Organon & Co. · NYSE

$13.76 +0.18% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Aug 21, 2026
Price · Chart
Our own end-of-day closes 38 sessions
$13.8 $13.4 30 Jun 21 Aug

The line runs $13.55 on 30 June through $13.76 on 21 August, on a scale from $13.4 to $13.8. Days the market did not trade hold the previous close, flat.

The chart above plots the price of OGN over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 38 sessions over that window: $13.55 on 30 June 2026 through $13.76 on 21 August 2026.

Market cap $3.6B
P/E (TTM) 17.6
52-week range $5.70 – $13.76
Avg volume 442.2K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Aug 21, 2026

OGN insider trades

SEC Form 4 · last 90 days · newest reported trade 5 Aug 2026
Open-market buys 0
Open-market sells 1
Net sold $200K
Non-trade filings 2
Date Insider Type Shares Value
05 Aug 2026 Drinane Juliana Papa Head of Mfg & Supply Sell 14,761 $200K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
11 Aug 2026 Arjona Ferreira Juan Camilo Head of R&D & CMO Option exercise 11,519
11 Aug 2026 Arjona Ferreira Juan Camilo Head of R&D & CMO Tax withheld 4,134 $56K

OGN reported financials

SEC EDGAR XBRL

OGN reported revenue of $6.2B for the fiscal year ended 31 Dec 2025. Net income over the same period was $187.0M.

Figure Reported Period
Revenue $6.2B 31 Dec 2025 fiscal year
Net income $187.0M 31 Dec 2025 fiscal year
Diluted EPS $0.72 31 Dec 2025 fiscal year
Total assets $13.2B 30 Jun 2026 at period end
Total equity $1.0B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

OGN earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.40 $1.56B
31 Mar 2026 Q1 2026 $0.55 $1.46B
31 Dec 2025 FY 2025 $0.72 $6.22B
30 Sep 2025 Q3 2025 $0.61 $1.60B
30 Jun 2025 Q2 2025 $0.56 $1.59B
31 Mar 2025 Q1 2025 $0.33 $1.51B
31 Dec 2024 FY 2024 $3.33 $6.40B
30 Sep 2024 Q3 2024 $1.38 $1.58B

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

OGN institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a OGN position for the quarter ended 30 Jun 2026 — a combined $180.0M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Man Group New position 4,180,500 $56.6M
Millennium Management Trimmed −49.2% shares 3,442,430 $46.6M
Balyasny Asset Management Added +908.1% shares 2,196,642 $29.7M
AQR Capital Management Trimmed −63.9% shares 1,245,588 $16.8M
Marshall Wace Held (±25%) −11.3% shares 828,133 $11.2M
D. E. Shaw & Co. Trimmed −72.8% shares 718,753 $9.7M
Citadel Advisors Trimmed −82.8% shares 344,359 $4.7M
Two Sigma Investments Trimmed −92.3% shares 241,392 $3.3M
GAMCO Investors New position 86,872 $1.2M
Tudor Investment Corp Trimmed −70.2% shares 11,180 $151K

Source: SEC EDGAR 13F filings

OGN fails-to-deliver

SEC CNS data

On 31 Aug 2026, 28,121 shares of OGN failed to deliver (about $387K).

Settlement date Shares failed Notional % of shares out
31 Aug 2026 28,121 $387K 0.011%
24 Aug 2026 10 $138 <0.001%
14 Aug 2026 153 $2K <0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in OGN

STOCK Act disclosures

The most recent congressional trade disclosed in OGN is a sale by Kevin Hern (house, OK), dated 05 Aug 2026.

Date Member Type Amount
05 Aug 2026 filed 10 Aug 2026 Kevin Hern house · Republican–OK Sale $1K–$15K

Source: U.S. House of Representatives financial disclosures